
Opinion|Videos|November 25, 2024
Current Landscape of Bispecific Therapies for RRMM
Key Takeaways
- Bispecific therapies target both tumor antigens and T-cell receptors, enhancing immune responses against myeloma cells in RRMM.
- Several bispecific antibodies are approved or in clinical trials, showing promise in overcoming resistance to conventional therapies.
Panelists discuss how bispecific T-cell–engaging therapies targeting BCMA, GPRC5D, and FcRH5 have emerged as novel immunotherapeutic approaches showing meaningful clinical activity for patients with heavily pretreated relapsed/refractory multiple
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following
- Provide a brief overview of the bispecific therapies currently available for the treatment of relapsed/refractory multiple myeloma (RRMM).
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
3
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5


























